AVEO Pharmaceuticals Says Secondary Endpoint In Phase 3 TIVO-3 Trial Was Not Mature At The Time Of PFS Analysis; Says At Time Of Preliminary Analysis, There Was No Statistically Significant Difference In Overall Survival